10/Prio



PATENT APPLICATION

MAR 3 1 2003

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re the Application of M. FLASHNER-BARAK

Group Art Unit:

1615

Application No.:

09/829,621

Examiner:

A. E. Pulliam

Filed:

April 10, 2001

Docket No.:

1662/52202

For:

METHOD AND COMPOSITION FOR TREATING CANCER BY

ADMINISTRATION OF APOPTOSIS-INDUCING

CHEMOTHERAPEUTIC AGENTS

INFORMATION DISCLOSURE STATEMENT

Director of the U.S. Patent and Trademark Office Washington, D.C. 20231

Sir:

Pursuant to 37 CFR § 1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. Unless otherwise indicated herein, one copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.

It is hereby certified that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in §1.56(c) more than three months prior to the filing of the information disclosure statement.

No fee is deemed to be necessary at this time. However, the Commissioner is hereby authorized to charge any payment due associated with this filing to Deposit Account No. 11-0600.

Date: 3/28/03

Respectfully submitted,

Ţ

KENYON & KENYON

W. David Wallace

Reg. No. 42,210

2